Hormonal
Regular physical activity, specifically at least 150 minutes per week of moderate-to-vigorous aerobic exercise combined with resistance training, improves blood glucose control and insulin action in individuals with type 2 diabetes.
To manage type 2 diabetes, aim for at least 150 minutes of moderate-to-vigorous aerobic exercise (like brisk walking) per week, spread across at least 3 days, ensuring no more than 2 days pass without activity. Add resistance training (weights or bands) 2-3 days a week. If you take insulin or certain diabetes medications, monitor your blood sugar and consult your doctor about adjusting your dose or eating carbs before/during exercise to prevent lows. If you are sedentary, get a check-up before starting intense exercise.
Persons with type 2 diabetes should undertake at least 150 min/week of moderate to vigorous aerobic exercise spread out over at least 3 days during the week... In addition to aerobic training, persons with type 2 diabetes should undertake moderate to vigorous resistance training at least 2–3 days/week.
Why this rating
The paper cites 'Randomized, controlled trials (overwhelming data)' (ACSM Category A) and 'Clear evidence from well-conducted... randomized, controlled trials' (ADA Level A).
Source
Exercise and Type 2 Diabetes
Sheri R. Colberg et al. · Diabetes Care · 2010
DOI 10.2337/dc10-1548
More from this paper
- Individuals with type 2 diabetes can safely perform exercise, provided they take precautions for specific complications such as retinopathy, neuropathy, and cardiovascular disease.Limited
- Structured lifestyle interventions combining physical activity and modest weight loss can lower the risk of developing type 2 diabetes by up to 58% in high-risk populations.Weak
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →